Insilicos Awarded Grant for Advanced Statistical Methods
Seattle, 5 February 2009 - Insilicos today announced that the National Institute of General Medical Sciences has awarded the company a grant to study a statistical method called Least Angle Regression, or LARS. LARS is a technique for producing stable predictions from data with a large number of dimensions. Such data is typical of Insilicos' biomedical research.
Dr. Chris Fraley is leading Insilicos' LARS research, which is a continuation of Fraley's work with Dr. Tim Hesterberg (now at Google) on the LARS method. Fraley's current LARS research emphasizes biomarker discovery applications.
"LARS is showing exciting results in life science and other areas," said Insilicos president Erik Nilsson. "Insilicos takes a systems biology approach to diagnosing disease, where we see disease as breakdown of molecular communication in the body. When you measure this breakdown, you have lots of different signals to choose from, different molecules you can measure. We use LARS as a way of selecting the most promising signals and using these signals to predict disease."
Insilicos has now received over $3 million in NIH grants, which support the company's research towards diagnostics for cardiovascular disease.
Insilicos LLC is a biomarker discovery and diagnostic development company, concentrating on cardiovascular disease.
For more information, visit the Insilicos web site www.insilicos.com or contact Insilicos at info@insilicos.com. 'Insilicos' 'PreClue," and 'Life Science Software' are trademarks of Insilicos LLC.
